Recent advances in pharmacotherapy for hypertriglyceridemia

Progress in Lipid Research

Volumn 56, Issue 1, 2014, Pages 47-66

  Sahebkar, Amirhossein ^a,b   Chew, Gerard T ^b   Watts, Gerald F ^b,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Dyslipidemia; Fat; Lipoprotein; Metabolism; Randomized controlled trial

Indexed keywords

ACYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; ALIPOGENE TIPARVOVEC; ANGIOPOIETIN LIKE PROTEIN INHIBITOR; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CURCUMINOID DERIVATIVE; DOCOSAHEXAENOIC ACID; EZETIMIBE; FIBRIC ACID DERIVATIVE; GFT 05; GFT 505; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INCRETIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PIOGLITAZONE; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; ROSIGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ADJUVANT THERAPY; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CATABOLISM; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DYSLIPIDEMIA; GENE REPLACEMENT THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOPROTEIN SECRETION; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RNA INTERFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG THERAPY; FATTY LIVER; MOLECULARLY TARGETED THERAPY; PANCREATITIS; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DRUG THERAPY; FATTY LIVER; HUMANS; HYPERTRIGLYCERIDEMIA; MOLECULAR TARGETED THERAPY; PANCREATITIS; TREATMENT OUTCOME;

EID: 84906653638     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2014.07.002     Document Type: Review

References (356)

1. M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, and A.L. Catapano et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
2. National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
3. L. Berglund, J.D. Brunzell, A.C. Goldberg, I.J. Goldberg, F. Sacks, and M.H. Murad et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 97 2012 2969 2989
4. T. Teramoto, J. Sasaki, S. Ishibashi, S. Birou, H. Daida, and S. Dohi et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version J Atheroscler Thromb 20 2013 517 523
5. M. Miller, N.J. Stone, C. Ballantyne, V. Bittner, M.H. Criqui, and H.N. Ginsberg et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
6. S.M. Grundy Obesity, metabolic syndrome, and cardiovascular disease J Clin Endocrinol Metab 89 2004 2595 2600
7. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. New Engl J Med. doi: 10.1056/NEJMoa1308027.
8. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. New Engl J Med. doi: 10.1056/NEJMoa1307095.
9. G.F. Watts, E.M. Ooi, and D.C. Chan Demystifying the management of hypertriglyceridemia Nat Rev Cardiol 10 2013 648 661
10. R.A. Hegele Plasma lipoproteins: genetic influences and clinical implications Nat Rev Genet 10 2009 109 121
11. R.A. Hegele, H.N. Ginsberg, M.J. Chapman, B.G. Nordestgaard, J.A. Kuivenhoven, and M. Averna et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management Lancet Diabetes Endocrinol S2213-8587 2013 70191 70198
12. G. Feussner, S. Piesch, and J. Dobmeyer Genetics of type III hyperlipoproteinemia Genet Epidemiol 14 1997 283 297
13. R.W. Mahley, and S.C. Rall Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism C.R. Scriber, A.L. Beaudet, W.S. Aly, O. Vallo, The metabolic and molecular basis of inherited disease 8th ed. 2001 McGraw-Hill New York 2835 2855
14. J.D. Brunzell, H.G. Schrott, A.G. Motulsky, and E.L. Bierman Myocardial infarction in the familial forms of hypertriglyceridemia Metabolism 25 1976 313 320
15. P. Pajukanta, H.E. Lilja, J.S. Sinsheimer, R.M. Cantor, A.J. Lusis, and M. Gentile et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1) Nat Genet 36 2004 371 376
16. J. Naukkarinen, C. Ehnholm, and L. Peltonen Genetics of familial combined hyperlipidemia Curr Opin Lipidol 17 2006 285 290
17. E.A. Rosenthal, J. Ranchalis, D.R. Crosslin, A. Burt, J.D. Brunzell, and A.G. Motulsky et al. Joint linkage and association analysis with exome sequence data implicates SLC25A40 in hypertriglyceridemia Am J Hum Genet 93 2013 1035 1045
18. S.J. Bredie, P.N. Demacker, and A.F. Stalenhoef Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity Eur J Clin Invest 27 1997 802 811
19. J. de Graaf, and A.F. Stalenhoef Defects of lipoprotein metabolism in familial combined hyperlipidaemia Curr Opin Lipidol 9 1998 189 196
20. A.D. Sniderman, M. Castro Cabezas, J. Ribalta, R. Carmena, and T.W.A. De Bruin et al. During the scientific sessions of the European Society for Clinical Investigation Eur J Clin Invest 2002 32 May 2001 71 73
21. H. Boman, W.R. Hazzard, J.J. Albers, A.G. Cooper, and U. Motulsky Frequency of monogenic forms of hyperlipidemia in a normal population Am J Hum Genet 27 1975 19A
22. M. Rizzo, and K. Berneis Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 12 2005 237 239
23. T.A. André, and J.P. Després Pathophysiology of human visceral obesity: an update Physiol Rev 93 2013 359 404
24. M. Snel, J.T. Jonker, J. Schoones, H. Lamb, A. de Roos, and H. Pijl et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions Int J Endocrinol 2012 2012 983814
25. R.M. Krauss, and Y.A. Kesaniemi Cardiovascular disease and hyperlipidaemia Curr Opin Lipidol 5 1994 249 251
26. M.S. Brown, and J.L. Goldstein Selective verse total insulin resistance Cell Metab 7 2008 95 96
27. K. Uyeda, and J.J. Repa Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis Cell Metab 4 2006 107 110
28. Y. Ido-Kitamura, T. Sasaki, M. Kobayashi, H.J. Kim, Y.S. Lee, and O. Kikuchi et al. Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of Chrebp O-glycosylation PLoS One 7 2012 e47231
29. J.D. Horton, J.L. Goldstein, and M.S. Brown SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver J Clin Invest 109 2002 1125 1131
30. C. Xiao, J. Hsieh, K. Adeli, and G.F. Lewis Gut-liver interaction in triglyceride-rich lipoprotein metabolism Am J Physiol Endocrinol Metab 301 2011 E429 E446
31. M. Adiels, S.O. Olofsson, M.R. Taskinen, and J. Borén Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome Arterioscler Thromb Vasc Biol 28 2008 1225 1236
32. C.J. Packard Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein Biochem Soc Trans 31 2003 1066 1069
33. D.C. Chan, M.M. Chen, E.M.M. Ooi, and G.F. Watts An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 62 2008 799 809
34. D.C. Chan, G.F. Watts, T.G. Redgrave, T.A. Mori, and P.H. Barrett Apolipoprotein B100 kinetics in visceral obesity: associations with plasma apolipoprotein CIII concentrations Metabolism 51 2002 1041 1046
35. P.A. Field, and G.F. Gibbons Decreased hepatic expression of the low-density lipoprotein (LDL) receptor and LDL receptor-related protein in aging rats is associated with delayed clearance of chylomicrons from the circulation Metabolism 49 2000 492 498
36. J. Altomonte, L. Cong, S. Harbaran, A. Richter, J. Xu, and M. Meseck et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism J Clin Invest 114 2004 1493 1503
37. J.H. Rapp, A. Lespine, R.L. Hamilton, N. Colyvas, A.H. Chaumeton, and J. Tweedie-Hardman et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque Arterioscler Thromb 14 1994 1767 1774
38. R.E. Pitas, T.L. Innerarity, and R.W. Mahley Foam cells in explants of atherosclerotic rabbit aortas have receptors for beta-very low density lipoproteins and modified low density lipoproteins Arterioscler Thromb Vasc Biol 3 1983 2 12
39. G.D. Norata, L. Grigore, S. Raselli, L. Redaelli, A. Hamsten, and F. Maggi et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies Atherosclerosis 193 2007 321 327
40. H.K. Shin, Y.K. Kim, K.Y. Kim, J.H. Lee, and K.W. Hong Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidasemediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol Circulation 109 2004 1022 1028
41. F.H. de Man, R. Nieuwland, A. van der Laarse, F. Romijn, A.H. Smelt, and J.A. Gevers Leuven et al. Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy Atherosclerosis 152 2000 407 414
42. G. Avellone, V. Di Garbo, R. Cordova, G. Raneli, R. De Simone, and G.D. Bompiani Fibrinolysis in hypertrigliceridemic subjects in response to venous occlusion Blood Coagul Fibrinolysis 4 1993 429 433
43. L. Wang, R. Gill, T.L. Pedersen, L.J. Higgins, J.W. Newman, and J.C. Rutledge Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation J Lipid Res 50 2009 204 213
44. I.J. Goldberg, R.H. Eckel, and R. McPherson Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 31 2011 1716 1725
45. C. Rask-Madsen, and C.R. Kahn Tissue-specific insulin signaling, metabolic syndrome and cardiovascular disease Arterioscler Thromb Vasc Biol 32 2012 2052 2059
46. K.C. Maki, H.E. Bays, and M.R. Dicklin Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence J Clin Lipidol 6 2012 413 426
47. J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, and J.H. Stein et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation Diabetes Care 31 2008 811 822
48. T.J. Anderson, J. Gregoire, R.A. Hegele, P. Couture, G.B. Mancini, and R. McPherson et al. 2012 Update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
49. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.C. Fruchart Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 1998 2088 2093
50. G.D. Kolovou, P.M. Kostakou, K.K. Anagnostopoulou, and D.V. Cokkinos Therapeutic effects of fibrates in postprandial lipemia Am J Cardiovasc Drugs 8 2008 243 255
51. J.C. Hogue, B. Lamarche, Y. Deshaies, A.J. Tremblay, J. Bergeron, and C. Gagne et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia Metabolism 57 2008 246 254
52. G.F. Watts, P.H. Barrett, J. Ji, A.P. Serone, D.C. Chan, and K.D. Kroft et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome Diabetes 52 2003 803 811
53. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
54. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, and P. Helo et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
55. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, and M.B. Elam et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group N Engl J Med 341 1999 410 418
56. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, and M.R. Taskinen et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
57. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
58. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
59. L.C. Lovat, M.B. Elam, R.P. Byington, M.E. Sweeney, J.M. Sperl-Hillen, and J. Fleg et al. Effect of fenofibrate therapy on cardiovascular disease in men versus women with type 2 diabetes in the ACCORD-Lipid trial Circulation 122 2010 A20114
60. E. Bruckert, J. Labreuche, D. Deplanque, P.J. Touboul, and P. Amarenco Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis J Cardiovasc Pharmacol 57 2011 267 272
61. M. Lee, J.L. Saver, A. Towfighi, J. Chow, and B. Ovbiagele Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis Atherosclerosis 217 2011 492 498
62. K. McKeage, G.M. Keating, D. Bhatnagar, M.B. Elam, M. Farnier, and S.M. Mohiuddin Fenofibrate: a review of its use in dyslipidemia Drugs 71 2011 1917 1946
63. R. Scott, R. O'Brien, G. Fulcher, C. Pardy, M. D'Emden, and D. Tse et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) study Diabetes Care 32 2009 493 498
64. M.P. Hermans Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD Diab Vasc Dis Res 8 2011 180 189
65. C. Glineur, B. Gross, B. Neve, C. Rommens, G.T. Chew, and F. Martin-Nizard et al. Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells Arterioscler Thromb Vasc Biol 33 2013 621 628
66. A. Zambon, and K. Cusi The role of fenofibrate in clinical practice Diab Vasc Dis Res 4 2007 S15 S20
67. A. Zampelas, D.B. Panagiotakos, C. Pitsavos, U.N. Das, C. Chrysohoou, and Y. Skoumas et al. Fish consumption among healthy adults is associated with decreased levels of inflammatory markers related to cardiovascular disease: the ATTICA study J Am Coll Cardiol 46 2005 120 124
68. A. Leaf, J.X. Kang, Y.F. Xiao, and G.E. Billman Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils Circulation 107 2003 246 252
69. C. von Schacky, P. Angerer, W. Kothny, K. Theisen, and H. Mudra The effect of dietary omega 3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 130 1999 554 562
70. S. Rizza, M. Tesauro, C. Cardillo, A. Galli, M. Iantorno, and F. Gigli et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes Atherosclerosis 206 2009 569 574
71. J.G. Robinson, and N.J. Stone Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids Am J Cardiol 98 2006 39i 49i
72. T.A. Mori Omega-3 fatty acids and hypertension in humans Clin Exp Pharmacol Physiol 33 2006 842 846
73. W.S. Harris, and D. Bulchandani Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17 2006 387 393
74. H.E. Bays Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians Drugs Today 44 2008 205 246
75. K.C. Maki, M.R. Dicklin, A.L. Lawless, and M.S. Reeves Omega-3 fatty acids for the treatment of elevated triglycerides Clin Lipidol 4 2009 425 437
76. P.M. Kris-Etherton, W.S. Harris, L.J. Appel, and M.S. Reeves For the American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757
77. H.E. Bays Fish oils in the treatment of dyslipidemia and cardiovascular disease P.O. Kwiterovich Jr. The John Hopkins textbook of dyslipidemia 2010 Lippincott Williams & Wilkins Philadelphia 245 257
78. A.C. Skulas-Ray, P.M. Kris-Etherton, W.S. Harris, J.P. Vanden Heuvel, P.R. Wagner, and S.G. West Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia Am J Clin Nutr 93 2011 243 252
79. E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review Atherosclerosis 189 2006 19 30
80. H.E. Bays, C.M. Ballantyne, J.J. Kastelein, J.L. Isaacsohn, R.A. Braeckman, and P.N. Soni Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial) Am J Cardiol 108 2011 682 690
81. J.J. Kastelein, K.C. Maki, A. Susekov, M. Ezhov, B.G. Nordestgaard, and B.N. Machielse et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very High TriglycErides (EVOLVE) trial J Clin Lipidol 8 2014 94 106
82. M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Saito, and Y. Ishikawa et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
83. Y. Saito, M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, and Y. Ishikawa et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS) Atherosclerosis 200 2008 135 140
84. M. Matsuzaki, T. Kita, H. Mabuchi, Y. Matsuzawa, N. Nakaya, and S. Oikawa et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia Circ J 66 2002 1087 1095
85. C.M. Albert, C.H. Hennekens, C.J. O'Donnell, U.A. Ajani, V.J. Carey, and W.C. Willett et al. Fish consumption and risk of sudden cardiac death JAMA 279 1998 23 28
86. D. Mozaffarian, and J.H. Wu Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events J Am Coll Cardiol 58 2011 2047 2067
87. P.E. Marik, and J. Varon Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review Clin Cardiol 32 2009 365 372
88. K.B. Filion, F. El Khoury, M. Bielinski, I. Schiller, N. Dendukuri, and J.M. Brophy Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials BMC Cardiovasc Disord 10 2010 24 29
89. S.M. Kwak, S.K. Myung, Y.J. Lee, and H.G. Seo Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials Arch Intern Med 172 2012 686 694
90. E.C. Rizos, E.E. Ntzani, E. Bika, M.S. Kostapanos, and M.S. Elisaf Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis JAMA 308 2012 1024 1033
91. M. Yokoyama, H. Origasa, and M. Matsuzaki et al. Japan EPA Lipid Intervention Study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
92. D. Kromhout, E.J. Giltay, and J.M. Geleijnse N-3 fatty acids and cardiovascular events after myocardial infarction N Engl J Med 363 2010 2015 2026
93. B. Rauch, R. Schiele, S. Schneider, F. Diller, N. Victor, and H. Gohlke et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction Circulation 122 2010 2152 2159
94. P. Galan, E. Kesse-Guyot, S. Czernichow, S. Briancon, J. Blacher, and S. Hercberg Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial BMJ 341 2010 c6273
95. T.M. Brasky, A.K. Darke, X. Song, C.M. Tangen, P.J. Goodman, and I.M. Thompson et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial J Natl Cancer Inst 105 2013 1132 1141
96. McCarty MF, DiNicolantonio JJ, Lavie CJ, O'Keefe JH. Omega-3 and prostate cancer: examining the pertinent evidence. Mayo Clin Proc. doi: 10.1016/j.mayocp.2013.10.029.
97. J.E. Torfadottir, U.A. Valdimarsdottir, L.A. Mucci, J.L. Kasperzyk, K. Fall, and L. Tryggvadottir et al. Consumption of fish products across the lifespan and prostate cancer risk PLoS One 8 2013 e59799
98. M.M. Epstein, J.L. Kasperzyk, L.A. Mucci, E. Giovannucci, A. Price, and A. Wolk et al. Dietary fatty acid intake and prostate cancer survival in Örebro County, Sweden Am J Epidemiol 176 2012 240 252
99. J. King, J. Crouse, J. Terry, T. Morgan, B. Spray, and N. Miller Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia Am J Med 97 1994 323 331
100. V.S. Kamanna, and M.L. Kashap Mechanism of action of niacin Am J Cardiol 101 2008 20B 26B
101. S. Lamon-Fava, M.R. Diffenderfer, P.H. Barrett, A. Buchsbaum, M. Nyaku, and K.V. Horvath et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins Arterioscler Thromb Vasc Biol 28 2008 1672 1678
102. J. Pang, D.C. Chan, S.J. Hamilton, V.S. Tenneti, G.F. Watts, and P.H.R. Barrett Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 34 2014 427 432
103. W.E. Boden, M.S. Sidhu, and P.P. Toth The therapeutic role of niacin in dyslipidemia management J Cardiovasc Pharmacol Ther 19 2014 141 158
104. The AIM-HIGH investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
105. Armitage J. HPS2-THRIVE: Randomized placebo-controlled trial of ER Niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. ACC 2013.
106. K.G. Tolman The safety of thiazolidinediones Expert Opin Drug Saf 10 2011 419 428
107. A. Rubenstrunk, R. Hanf, and D.W. Hum et al. Safety issues and prospects for future generations of PPAR modulators Biochim Biophys Acta 1771 2007 1065 1081
108. N. Chalasani, Z. Younossi, and J.E. Lavine et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
109. M. Monami, V. Vitale, M.L. Ambrosio, N. Bartoli, G. Toffanello, and B. Ragghianti et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials Adv Ther 29 2012 736 746
110. M. Hanefeld The role of pioglitazone in modifying the atherogenic lipoprotein profile Diabetes Obes Metab 11 2009 742 756
111. A. Consoli, and G. Formoso Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes Metab 15 2013 967 977
112. B. Sinha, and S. Ghosal Pioglitazone-do we really need it to manage type 2 diabetes? Diabetes Metab Syndr 7 2013 52 55
113. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. MacFarlane et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
114. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N Engl J Med 335 1996 1001 1009
115. F.M. Sacks, A.M. Tonkin, J. Shepherd, E. Braunwald, S. Cobbe, and C.M. Hawkins et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
116. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
117. C.M. Ballantyne, A.G. Olsson, T.J. Cook, M.F. Mercuri, T.R. Pedersen, and J. Kjekshus Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
118. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr, and J.J. Kastelein et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
119. G. Savarese, A.M. Gotto Jr, S. Paolillo, C. D'Amore, T. Losco, and F. Musella et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis J Am Coll Cardiol 62 2013 2090 2099
120. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
121. K.C. Maki, H.E. Bays, and M.R. Dicklin Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence J Clin Lipidol 6 2012 413 426
122. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, and C. Pollicino et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
123. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
124. R.J. Glynn, W. Koenig, B.G. Nordestgaard, J. Shepherd, and P.M. Ridker Rosuvastatin for primary prevention in older individuals with high C-reactive protein and low LDL levels: exploratory analysis of a randomized trial Ann Intern Med 152 2010 488 496
125. E.A. Stein, M. Lane, and P. Laskarzewski Comparison of statins in hypertriglyceridemia Am J Cardiol 81 1998 66B 69B
126. D.C. Chan, G.F. Watts, P.H.R. Barrett, I.J. Martins, A.P. James, and J.C.L. Mamo et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test J Lipid Res 43 2002 706 712
127. H.N. Ginsberg Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia J Clin Endocrinol Metab 91 2006 383 392
128. G.F. Watts, and F. Karpe Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient Heart 97 2011 350 356
129. M. Naples, C. Baler, M. Lino, J. Iqbal, M.M. Hussain, and K. Adeli Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance Am J Physiol Gastrointest Liver Physiol 302 2012 1043 1052
130. M. Adiels, M.R. Taskinen, C. Packard, M.J. Caslake, A. Soro-Paavonen, and J. Westerbacka et al. Overproduction of large VLDL particles is driven by increased liver fat content in man Diabetologia 49 2006 755 765
131. D.C. Chan, G.F. Watts, S.K. Gan, E.M.M. Ooi, and P.R.R. Barrett Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet Diabetes Care 33 2010 1134 1139
132. N. Ewald, and H.U. Kloer Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis Clin Res Cardiol Suppl 7 2012 31 35
133. N. Ewald, and H.U. Kloer Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis Clin Res Cardiol 7 2012 S31 S35
134. L.A. Adams, and P. Angulo Treatment of non-alcoholic fatty liver disease Postgrad Med J 82 2006 315 322
135. A. Brea, and J. Puzo Non-alcoholic fatty liver disease and cardiovascular risk Int J Cardiol 167 2013 1109 1117
136. H. Chatrath, R. Vuppalanchi, and N. Chalasani Dyslipidemia in patients with nonalcoholic fatty liver disease Semin Liver Dis 32 2012 22 29
137. K.J. Schwenger, and J.P. Allard Clinical approaches to non-alcoholic fatty liver disease World J Gastroenterol 20 2014 1712 1723
138. V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, and K. Kargiotis et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 376 2010 1916 1922
139. M. Itoh, T. Suganami, N. Satoh, K. Tanimoto-Koyama, X. Yuan, and M. Tanaka et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects Arterioscler Thromb Vasc Biol 27 2007 1918 1925
140. N. Tanaka, K. Sano, A. Horiuchi, E. Tanaka, K. Kiyosawa, and T. Aoyama Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis J Clin Gastroenterol 42 2008 413 418
141. M. Capanni, F. Calella, M.R. Biagini, S. Genise, L. Raimondi, and G. Bedogni et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study Aliment Pharmacol Ther 23 2006 1143 1151
142. L. Spadaro, O. Magliocco, D. Spampinato, S. Piro, C. Oliveri, and C. Alagona et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease Dig Liver Dis 40 2008 194 199
143. G.L. Vega, M. Chandalia, L.S. Szczepaniak, and S.M. Grundy Effects of N-3 fatty acids on hepatic triglyceride content in humans J Invest Med 56 2008 780 785
144. G.S. Masterton, J.N. Plevris, and P.C. Hayes Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease Aliment Pharmacol Ther 31 2010 679 692
145. F.S. Zhu, S. Liu, X.M. Chen, Z.G. Huang, and D.W. Zhang Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia World J Gastroenterol 14 2008 6395 6400
146. H.M. Parker, N.A. Johnson, C.A. Burdon, J.S. Cohn, H.T. O'Connor, and J. George Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis J Hepatol 56 2012 944 951
147. B. Cariou, Y. Zaïr, B. Staels, and E. Bruckert Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism Diabetes Care 34 2011 2008 2014
148. U. Dressel, T.L. Allen, J.B. Pippal, P.R. Rohde, P. Lau, and G.E. Muscat The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells Mol Endocrinol 17 2003 2477 2493
149. J. Rip, M.C. Nierman, C.J. Ross, J.W. Jukema, M.R. Hayden, and J.J. Kastelein et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation Arterioscler Thromb Vasc Biol 26 6 2006 Jun 1236 1245
150. S.E. Gagné, M.G. Larson, S.N. Pimstone, E.J. Schaefer, J.J. Kastelein, and P.W. Wilson et al. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study Clin Genet 55 6 1999 Jun 450 454
151. T. Tanaka, J. Yamamoto, S. Iwasaki, H. Asaba, H. Hamura, and Y. Ikeda et al. Activation of peroxisome proliferator-activated receptor delta induces fatty
152. Y.X. Wang, C.H. Lee, S. Tiep, R.T. Yu, J. Ham, and H. Kang et al. Peroxisomeproliferator-activated receptor delta activates fat metabolism to prevent obesity Cell 113 2003 159 170
153. S.M. Reilly, and C.H. Lee PPAR delta as a therapeutic target in metabolic disease FEBS Lett 582 2008 26 31
154. S. Luquet, J. Lopez-Soriano, D. Holst, A. Fredenrich, J. Melki, and M. Rassoulzadegan et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability FASEB J 17 2003 2299 2301
155. C.H. Lee, P. Olson, A. Hevener, I. Mehl, L.W. Chong, and J.M. Olefsky et al. PPARdelta regulates glucose metabolism and insulin sensitivity Proc Natl Acad Sci U S A 103 2006 3444 3449
156. D.L. Sprecher, C. Massien, G. Pearce, A.N. Billin, I. Perlstein, and T.M. Willson et al. Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist Arterioscler Thromb Vasc Biol 27 2007 359 365
157. U. Risérus, D. Sprecher, T. Johnson, E. Olson, S. Hirschberg, and A. Liu et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men Diabetes 57 2008 332 339
158. B. Staels, A. Rubenstrunk, B. Noel, G. Rigou, P. Delataille, and L.J. Millatt et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis Hepatology 58 2013 1941 1952
159. S.E. Nissen, K. Wolski, and E.J. Topol Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus JAMA 294 2005 2581 2586
160. AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2013-11-11.
161. P. Sanwald-Ducray, X. Liogier D'ardhuy, C. Jamois, and L. Banken Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study Clin Pharmacol Ther 88 2010 197 203
162. R.R. Henry, A.M. Lincoff, S. Mudaliar, M. Rabbia, C. Chognot, and M. Herz Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study Lancet 374 2009 126 135
163. A.M. Lincoff, J.C. Tardif, G.G. Schwartz, S.J. Nicholls, L. Rydén, and B. Neal et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial JAMA 2014 10.1001/jama.2014.3321
164. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
165. D.J. Drucker The biology of incretin hormones Cell Metab 3 2006 153 165
166. R.E. Amori, J. Lau, and A.G. Pittas Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 2007 194 206
167. D. Dicker DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors Diabetes Care 34 2011 S276 S278
168. D.C. Klonoff, J.B. Buse, L.L. Nielsen, X. Guan, C.L. Bowlus, and J.H. Holcombe et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 24 2008 275 286
169. N. Matikainen, S. Mänttäri, A. Schweizer, A. Ulvestad, D. Mills, and B.E. Dunning et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 2006 2049 2057
170. S.L. Schwartz, R.E. Ratner, D.D. Kim, Y. Qu, L.L. Fechner, and S.M. Lenox et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study Clin Ther 30 2008 858 867
171. E.A. Schwartz, J. Koska, M.P. Mullin, I. Syoufi, D.C. Schwenke, and P.D. Reaven Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus Atherosclerosis 212 2010 217 222
172. M. Monami, C. Lamanna, C.M. Desideri, and E. Mannucci DPP-4 inhibitors and lipids: systematic review and meta-analysis Adv Ther 29 2012 14 25
173. C.T. Xiao, R.H.J. Bandsma, S. Dash, L. Szeto, and G.F. Lewis Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans Arterioscler Thromb Vasc Biol 32 2012 1513 1519
174. X. Qin, H. Shen, M. Liu, Q. Yang, S. Zheng, and M. Sabo et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats Am J Physiol Gastrointest Liver Physiol 288 2005 G943 G949
175. S. Farr, and K. Adeli Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states Curr Opin Lipidol 23 2012 56 61
176. R.E. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, and S. Filetti et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 2010 1447 1456
177. R.A. DeFronzo, T. Okerson, P. Viswanathan, X. Guan, J.H. Holcombe, and L. MacConell Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 24 2008 2943 2952
178. J.R. Petrie The cardiovascular safety of incretin-based therapies: a review of the evidence Cardiovasc Diabetol 12 2013 130
179. S.P. Marso, J.B. Lindsey, J.M. Stolker, J.A. House, G. Martinez Ravn, and K.F. Kennedy et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical development studies Diab Vasc Dis Res 8 2011 237 240
180. S. Agarwal, A. Parashar, and V. Menon Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate Am J Cardiovasc Drugs 2014 10.1007/s40256-014-0070-7
181. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
182. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, and G.L. Bakris et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 2013 1327 1335
183. J.R. Wetterau, and D.B. Zilversmit A triglyceride and cholesteryl ester transfer protein associated with liver microsomes J Biol Chem 259 1984 10863 10866
184. M.M. Hussain, J. Shi, and P. Dreizen Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly J Lipid Res 44 2003 22 32
185. M.M. Hussain, and A. Bakillah New approaches to target microsomal triglyceride transfer protein Curr Opin Lipidol 19 2008 572 578
186. D. Aggarwal, K.L. West, T.L. Zern, S. Shrestha, M. Vergara-Jimenez, and M.L. Fernandez JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs BMC Cardiovasc Disord 5 2005 30
187. E. Kim, S. Campbell, and O. Schueller et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile J Pharmacol Exp Ther 337 2011 775 785
188. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. doi: 10.1111/1755-5922.12075.
189. H.R. Patil, F.J. Al Badarin, H.A. Al Shami, S.K. Bhatti, C.J. Lavie, and D.S. Bell et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am J Cardiol 110 2012 826 833
190. Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, et al. incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI53) of the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin. Diabetes Care. doi: 10.2337/dc13-2546.
191. J.R. Wetterau, L.P. Aggerbeck, M.E. Bouma, C. Eisenberg, A. Munck, and M. Hermier et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia Science 258 1992 999 1001
192. D.J. Rader, and H.B. Brewer Jr. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin emetabolism from a rare genetic disease JAMA 270 1993 865 869
193. M. Cuchel, L.T. Bloedon, P.O. Szapary, D.M. Kolansky, M.L. Wolfe, and A. Sarkis et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2007 148 156
194. M. Cuchel, E.A. Meagher, H. du Toit Theron, D.J. Blom, A.D. Marais, and R.A. Hegele et al. Phase 3 HoFH lomitapide study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46
195. F.F. Samaha, J. McKenney, L.T. Bloedon, W.J. Sasiela, and D.J. Rader Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia Nat Clin Pract Cardiovasc Med 5 2008 497 505
196. F.M. Sacks, M. Stanesa, and R.A. Hegele Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide JAMA Intern Med 174 2014 443 447
197. S.J. Stone, H. Myers, B.E. Brown, S.M. Watkins, K.R. Feingold, and P.M. Elias et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice J Biol Chem 279 2004 11767 11776
198. H.C. Chen, and R.V. Farese Jr. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice Arterioscler Thromb Vasc Biol 25 2005 482 486
199. S.J. Smith, S. Cases, D.R. Jensen, H.C. Chen, E. Sande, and B. Tow et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT Nat Genet 25 2000 87 90
200. H.C. Chen, S.J. Smith, Z. Ladha, D.R. Jensen, L.D. Ferreira, and L.K. Pulawa et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1 J Clin Invest 109 2002 1049 1055
201. H.C. Chen, M. Rao, M.P. Sajan, M. Standaert, Y. Kanoh, and A. Miura et al. The role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking acyl coenzyme A:diacylglycerol acyltransferase 1 Diabetes 53 2004 1445 1451
202. C. Meyers, D. Gaudet, K. Tremblay, A. Amer, J. Chen, and F. Aimin et al. The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome J Clin Lipidol 6 2012 266 267
203. H. Denison, C. Nilsson, M. Kujacic, L. Löfgren, C. Karlsson, and M. Knutsson et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study Diabetes Obes Metab 15 2013 136 143
204. P.N. Durrington Hyperlipidaemia diagnosis and management 3rd ed. 2008 Hodder Arnold London
205. J.S. Millar, M.E. Brousseau, M.R. Diffenderfer, P.H. Barrett, F.K. Welty, and A. Faruqi et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism Arterioscler Thromb Vasc Biol 26 2006 1350 1356
206. J.S. Millar, M.E. Brousseau, M.R. Diffenderfer, P.H.R. Barrett, F.K. Welty, and J.S. Cohen et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism J Lipid Res 49 2008 543 549
207. M.R. Diffenderfer, M.E. Brousseau, J.S. Millar, P.H.R. Barrett, C. Nartsupha, and P.M. Schaefer et al. Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism J Lipid Res 53 2012 1190 1199
208. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, and M. Komajda et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
209. B. Hewing, and E.A. Fisher Rationale for cholesteryl ester transfer protein inhibition Curr Opin Lipidol 23 2012 372 376
210. M. Vergeer, M.L. Bots, S.I. van Leuven, D.C. Basart, E.J. Sijbrands, and G.W. Evans et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials Circulation 118 2008 2515 2522
211. M.J. Forrest, D. Bloomfield, R.J. Briscoe, P.N. Brown, A.M. Cumiskey, and J. Ehrhart et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 2008 1465 1473
212. D.J. Rader, and H.D.L. Illuminating Is it still a viable therapeutic target? N Engl J Med 357 2007 2180 2183
213. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, and A.M. Gotto et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
214. R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon, and J. Cote et al. Effect of the cholesteryl ester transfer protein inhibitor anacetrapib, on lipoproteins in patients with dyslipidemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies Lancet 370 2007 1907 1914
215. D. Bloomfield, G.L. Carlson, A. Sapre, D. Tribble, J.M. McKenney, and T.W. Littlejohn 3rd et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2009 352 360
216. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, K.A. Krueger, M.D. Wang, and M. Shao et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
217. H. Wang, and R.H. Eckel Lipoprotein lipase: from gene to obesity Am J Physiol Endocrinol Metab 297 2009 E271 E288
218. A. Chait, and J.D. Brunzell Severe hypertriglyceridemia: role of familial and acquired disorders Metabolism 32 1983 209 214
219. N.F. Ullrich, J.Q. Purnell, and J.D. Brunzell Adipose tissue fatty acid composition in humans with lipoprotein lipase deficiency J Investig Med 49 2001 273 275
220. D.N. Nevin, J.D. Brunzell, and S.S. Deeb The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity Arterioscler Thromb 14 1994 869 994
221. P. Julien, M.C. Vohl, D. Gaudet, C. Gagné, G. Lévesque, and J.P. Després et al. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency Diabetes 46 1997 2063 2068
222. A. Koster, Y.B. Chao, M. Mosior, A. Ford, P.A. Gonzalez-DeWhitt, and J.E. Hale et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism Endocrinology 146 2005 4943 4950
223. C. Li Genetics and regulation of angiopoietin-like proteins 3 and 4 Curr Opin Lipidol 17 2006 152 156
224. T. Shimizugawa, M. Ono, M. Shimamura, K. Yoshida, Y. Ando, and R. Koishi et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase J Biol Chem 277 2002 33742 33748
225. M. Shimamura, M. Matsuda, H. Yasumo, M. Okazaki, K. Fujimoto, and K. Kono et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase Arterioscler Thromb Vasc Biol 27 2007 366 372
226. L. Lichtenstein, J.F. Berbee, S.J. van Dijk, K.W. van Dijk, A. Bensadoun, and I.P. Kema et al. Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake Arterioscler Thromb Vasc Biol 27 2007 2420 2427
227. K. Fujimoto, R. Koishi, T. Shimizugawa, and Y. Ando Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity Exp Anim 55 2006 27 34
228. E.C. Lee, U. Desai, G. Gololobov, S. Hong, X. Feng, and X.C. Yu et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL) J Biol Chem 284 2009 13735 13745
229. U. Desai, E.C. Lee, K. Chung, C. Gao, J. Gay, and B. Key et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice Proc Natl Acad Sci U S A 104 2007 11766 11771
230. K.N. Maxwell, and J.L. Breslow Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype Proc Natl Acad Sci USA 101 2004 7100 7105
231. S.W. Park, Y.A. Moon, and J.D. Horton Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver J Biol Chem 279 2004 50630 50638
232. A. Roubtsova, M.N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, and C. Lazure et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue Arterioscler Thromb Vasc Biol 31 4 2011 Apr 785 791
233. G. Lambert, B. Sjouke, B. Choque, J.J. Kastelein, and G.K. Hovingh The PCSK9 decade J Lipid Res 53 2012 2515 2524
234. G.D. Norata, G. Tibolla, and A.L. Catapano Targeting PCSK9 for hypercholesterolemia Ann Rev Pharmacol Toxicol 54 2014 273 293
235. A. Sahebkar, and G.F. Watts New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther 27 2013 559 567
236. A. Sahebkar, and G.F. Watts New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes Clin Ther 35 2013 1082 1098
237. R.P. Giugliano, N.R. Desai, P. Kohli, W.J. Rogers, R. Somaratne, and F. Huang et al. Efficacy, safety, and tolerability of amonoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
238. C. Le May, S. Kourimate, C. Langhi, M. Chétiveaux, A. Jarry, and C. Comera et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia Arterioscler Thromb Vasc Biol 29 2009 684 690
239. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, et al. PCSK9 promotes intestinal overproduction of triglyceride-rich apolipoprotein-B lipoproteins through both LDL-receptor dependent and independent mechanisms. Circulation. doi:10.1161/CIRCULATIONAHA.113.006720.
240. M.J. Koren, R. Scott, J.B. Kim, B. Knusel, T. Liu, and L. Lei et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
241. D. Sullivan, A.G. Olsson, R. Scott, J.B. Kim, A. Xue, and V. Gebski et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
242. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
243. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
244. K. Fitzgerald, M. Frank-Kamenetsky, S. Shulga-Morskaya, A. Liebow, B.R. Bettencourt, and J.E. Sutherland et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 2014 60 68
245. A. Roubtsova, M.N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, and C. Lazure et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue (2011) Arterioscler Thromb Vasc Biol 31 2014 785 791
246. T. Takazawa, T. Yamauchi, A. Tsuchida, M. Takata, Y. Hada, and M. Iwabu et al. Peroxisome proliferator-activated receptor γ agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes J Biol Chem 284 2009 30049 30057
247. D.J. Blom, T. Hala, M. Bolognese, M.J. Lillestol, P.D. Toth, and L. Burgess et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
248. H. Yagyu, E. Peer Lutz, Y. Kako, S. Marks, Y. Hu, and S.Y. Choi Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency J Biol Chem 277 2002 10037 10043
249. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr, and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
250. J. Cohen, A. Pertsemlidis, I.K. Kotowski, R. Graham, C.K. Garcia, and H.H. Hobbs Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 Nat Genet 37 2005 161 165
251. J.J. Kastelein, M.K. Wedel, B.F. Baker, J. Su, J.D. Bradley, and R.Z. Yu et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by shortterm administration of an antisense inhibitor of apolipoprotein B Circulation 114 2006 1729 1735
252. F. Akdim, D.L. Tribble, J.D. Flaim, R. Yu, J. Su, and R.S. Geary et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia Eur Heart J 32 2011 2650 2659
253. F. Akdim, E.S. Stroes, E.J. Sijbrands, D.L. Tribble, M.D. Trip, and J.W. Jukema et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 55 2010 1611 1618
254. M.E. Visser, G. Wagener, B.F. Baker, R.S. Geary, J.M. Donovan, and U.H. Beuers et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial Eur Heart J 33 2012 1142 1149
255. M.E. Visser, F. Akdim, D.L. Tribble, A.J. Nederveen, T.J. Kwoh, and J.J. Kastelein et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia J Lipid Res 51 2010 1057 1062
256. F. Akdim, M.E. Visser, D.L. Tribble, B.F. Baker, E.S. Stroes, and R. Yu et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia Am J Cardiol 5 2010 1413 1419
257. F.J. Raal, R.D. Santos, D.J. Blom, A.D. Marais, M.J. Charng, and W.C. Cromwell et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
258. J.C. Tardif, M. Mcgowan, R. Ceska, H. Sorana, I. Gouni-Berthold, and G. Wegener et al. Apolipoprotein B synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia J Am Coll Cardiol 57 2011 E492
259. M.P. McGowan, J.C. Tardif, R. Ceska, L.J. Burgess, H. Soran, and I. Gouni-Berthold et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS One 7 2012 e49006
260. E.A. Stein, R. Dufour, C. Gagne, D. Gaudet, C. East, and J.M. Donovan et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 2012 2283 2292
261. J.D. Furtado, M.K. Wedel, and F.M. Sacks Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins J Lipid Res 53 2012 784 791
262. K.F. Petersen, S. Dufour, A. Hariri, C. Nelson-Williams, J.N. Foo, and X.M. Zhang et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease N Engl J Med 362 2010 1082 1089
263. R.L. Pollex, M.R. Ban, T.K. Young, P. Bjerregaard, S.S. Anand, and S. Yusuf et al. Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample BMC Med Genet 8 2007 80
264. M. Miller, J. Rhyne, H. Chen, V. Beach, R. Ericson, and K. Luthra et al. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome Arch Med Res 38 2007 444 451
265. T.I. Pollin, C.M. Damcott, H. Shen, S.H. Ott, J. Shelton, and R.B. Horenstein et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection Science 322 2008 1702 1705
266. H. Liu, C. Labeur, C.F. Xu, R. Ferrell, L. Lins, and R. Brasseur et al. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr J Lipid Res 41 2000 1760 1771
267. M. Sundaram, S. Zhong, M. Bou Khalil, H. Zhou, Z.G. Jiang, and Y. Zhao et al. Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia J Lipid Res 51 2010 1524 1534
268. G. Atzmon, M. Rincon, C.B. Schechter, A.R. Shuldiner, R.B. Lipton, and A. Bergman et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans PLoS Biol 4 2006 e113
269. M.J. Graham, R.G. Lee, T.A. Bell 3rd, W. Fu, A.E. Mullick, and V.J. Alexander et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ Res 112 2013 1479 1490
270. M. Sundaram, S. Zhong, M. Bou Khalil, P.H. Links, Y. Zhao, and J. Iqbal et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions J Lipid Res 51 2010 150 161
271. G.S. Getz, G.D. Wool, and C.A. Reardon HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders Curr Pharm Des 16 2010 3173e84
272. O.F. Sharifov, G. Nayyar, D.W. Garber, S.P. Handattu, V.K. Mishra, and D. Goldberg et al. Apolipoprotein E mimetics and cholesterol-lowering properties Am J Cardiovasc Drugs 11 2011 371 381
273. G. Nayyar, D.W. Garber, M.N. Palgunachari, C.E. Monroe, T.D. Keenum, and S.P. Handattu et al. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice Atherosclerosis 224 2012 326 331
274. G. Nayyar, S.P. Handattu, C.E. Monroe, M. Chaddha, G. Datta, and V.K. Mishra et al. Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects Atherosclerosis 213 2010 449 457
275. S.P. Handattu, G. Nayyar, D.W. Garber, M.N. Palgunachari, C.E. Monroe, and T.D. Keenum et al. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice Atherosclerosis 227 2013 58 64
276. H. Gupta, C.R. White, S. Handattu, D.W. Garber, G. Datta, and M. Chaddha et al. Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits Circulation 111 2005 3112 3118
277. J.C. Fruchart Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists Cardiovasc Diabetol 12 2013 [art. no. 82]
278. A. Sahebkar, and G.F. Watts Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster Diabetes Obes Metab 2014 10.1111/dom.12277
279. A. Sahebkar, G.T. Chew, and G.F. Watts New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease Expert Opin Pharmacother 15 2014 493 503
280. Ishibashi S, Arai H, Yamashita S, Araki E, Yamada N. Benefical effects of K-877, a potent and highly selective PPARα agonist, on plasma lipoprotein profile in patients with atherogenic dyslipidemia. (Abstract 525). 80th EAS Congress 2012.
281. Ishibashi S, Yamashita S, Arai H, Araki E, Yamada N. Suppression of postprandial triglyceride, remnant-like particles-cholesterol (RLP-C) and ApoB48 surge by K-877, a potent and highly selective PPARα agonist. Abstract 618.
282. H.E. Bays, S. Schwartz, T. Littlejohn 3rd, B. Kerzner, R.M. Krauss, and D.B. Karpf et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin J Clin Endocrinol Metab 96 2011 2889 2897
283. Y.J. Choi, B.K. Roberts, X. Wang, J.C. Geaney, S. Naim, and K. Wojnoonski et al. Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia Atherosclerosis 220 2012 470 476
284. J.D. Brunzell, and S.S. Deeb Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency A.L. Beaudet<, W.S. Sly, D. Valle, C.R. Scriver, The metabolic basis of inherited disease 2001 McGraw-Hill New York 2789 2816
285. D. Gaudet, J. de Wal, K. Tremblay, S. Déry, S. van Deventer, and A. Freidig et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency Atheroscler Suppl 11 2010 55 60
286. E.S. Stroes, M.C. Nierman, J.J. Meulenberg, R. Franssen, J. Twisk, and C.P. Henny et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase deficient patients Arterioscler Thromb Vasc Biol 28 2008 2303 2304
287. D. Gaudet, J. Méthot, S. Déry, D. Brisson, C. Essiembre, and G. Tremblay et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial Gene Ther 20 2013 361 369
288. A.C. Carpentier, F. Frisch, S.M. Labbé, R. Gagnon, J. de Wal, and S. Greentree et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients J Clin Endocrinol Metab 97 2012 1635 1644
289. W.S. Harris, H.N. Ginsberg, N. Arunakul, N.S. Shachter, S.L. Windsor, and M. Adams et al. Safety and efficacy of Omacor in severe hypertriglyceridemia J Cardiovasc Risk 4 1997 385 391
290. H.J. Pownall, D. Brauchi, C. Kilinç, K. Osmundsen, Q. Pao, and C. Payton-Ross et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins Atherosclerosis 143 1999 285 297
291. M.H. Davidson, E.A. Stein, H.E. Bays, K.C. Maki, R.T. Doyle, and R.A. Shalwitz et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 135e67
292. C.M. Ballantyne, H.E. Bays, J.J. Kastelein, E. Stein, J.L. Isaacsohn, and R.A. Braeckman et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) Am J Cardiol 110 2012 984 992
293. Nobili V, Carpino G, Alisi A, De vito R, Franchitto A, Alpini G, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLOS One. Doi: 10.1371/journal.pone.0088005.
294. D.J. Rader, R.L. Dunbar, K.C. Maki, T.A. Jacobson, T. Kling, and M.H. Davidson Apolipoprotein C-III is significantly reduced by prescription omega-3 free fatty acids (Epanova) in patients with severe hypertriglyceridemia and changes correlate with increases in LDL-C: a sub-analysis of the EVOLVE trial (abstract) Circulation 126 2012 A19030
295. I. Ikeda, E. Sasaki, H. Yasunami, S. Nomiyama, M. Nakayama, and M. Sugano et al. Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl
296. L.D. Lawson, and B.G. Hughes Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters Biochem Biophys Res Commun 152 1988 328 335
297. L.D. Lawson, and B.G. Hughes Absorption of eicosapentaenoic acid and docosahexaenoic acid from docosa oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal Biochem Biophys Res Commun 156 1988 960 963
298. B. Beckermann, M. Beneke, and I. Seitz Comparative bioavailability of eicosapentaenoic acid and docosahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers Arzneimittelforschung 40 1990 700 704
299. M.H. Davidson, J. Johnson, M.W. Rooney, M.L. Kyle, and D.F. Kling A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study J Clin Lipidol 6 2012 573 584
300. J.J. Kastelein, K.C. Maki, A. Susekov, M. Ezhov, B.G. Nordestgaard, and D. Kling et al. Dose response of a novel free-fatty acid formulation of omega-3 for the management of dyslipidemia in patients with severe hypertriglyceridemia: EpanoVa fOr Lowering Very High TriglycErides (the EVOLVE trial) (Abstract 16374) Circulation 126 2012
301. K.C. Maki, D.G. Orloff, S.J. Nicholls, R.L. Dunbar, E.M. Roth, and D. Curcio et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial) Clin Ther 35 2013 1400 1411
302. D.J. Rader, R.L. Dunbar, K.C. Maki, T.A. Jacobson, D. Kling, and M.H. Davidson Apolipoprotein C-III is significantly reduced by prescription omega-3 free fatty acids (Epanova) in patients with severe hypertriglyceridemia and changes correlate with increases in LDL-C: a sub-analysis of the EVOLVE trial (abstract) Circulation 126 2012 A19030
303. A. Shehzad, G. Rehman, and Y.S. Lee Curcumin in inflammatory diseases Biofactors 39 2013 69 77
304. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. doi: 10.1002/ptr.5045.
305. Y. Panahi, A. Sahebkar, S. Parvin, and A. Saadat A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications Ann Clin Biochem 49 2012 580 588
306. A. Sahebkar, A. Mohammadi, A. Atabati, S. Rahiman, S. Tavallaie, and M. Iranshahi et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals Phytother Res 27 2013 1883 1888
307. Y. Panahi, A. Sahebkar, M. Amiri, S.M. Davoudi, F. Beiraghdar, and S.L. Hoseininejad et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial Br J Nutr 108 2012 1272 1279
308. A. Shehzad, J. Lee, and Y.S. Lee Curcumin in various cancers Biofactors 39 2013 56 68
309. Y. Panahi, A. Saadat, F. Beiraghdar, S.M. Hosseini Nouzari, H.R. Jalalian, and A. Sahebkar Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: a randomized double-blind placebo-controlled trial J Funct Foods 6 2014 615 622
310. Panahi Y, Saadat A, Beiraghdar F, Sahebkar. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res. doi: 10.1002/ptr.5149.
311. A. Monroy, G.J. Lithgow, and S. Alavez Curcumin and neurodegenerative diseases Biofactors 39 2013 122 132
312. M. Iranshahi, A. Sahebkar, S.T. Hosseini, M. Takasaki, T. Konoshima, and H. Tokuda Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo Phytomedicine 17 2010 269 273
313. Panahi Y, Rahimnia A, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res. doi: 10.1002/ptr.5174.
314. Badeli R, Panahi Y, Karami N, Sahebkar A. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res. http://dx.doi.org/10.1002/ptr.5211.
315. G. Srivastava, and J.L. Mehta Currying the heart: Curcumin and cardioprotection J Cardiovasc Pharmacol Ther 14 2009 22 27
316. A. Sahebkar Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39 2 2013 197 208
317. A. Sahebkar Molecular mechanisms for curcumin benefits against ischemic injury Fertil Steril 94 2010 e75 e76
318. A. Shehzad, and Y.S. Lee Curcumin: multiple molecular targets mediate multiple pharmacological actions - a review Drugs Future 35 2010 113 119
319. J.M. Zingg, S.T. Hasan, and M. Meydani Molecular mechanisms of hypolipidemic effects of curcumin Biofactors 39 2013 101 121
320. A. Sahebkar Curcuminoids for the management of hypertriglyceridaemia Nat Rev Cardiol 11 2014 123
321. T. Nishiyama, T. Mae, H. Kishida, M. Tsukagawa, Y. Mimaki, and M. Kuroda et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice J Agric Food Chem 53 2005 959 963
322. M.Y. Um, K.H. Hwang, J. Ahn, and T.Y. Ha Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase Basic Clin Pharmacol Toxicol 113 2013 152 157
323. S.K. Shin, T.Y. Ha, R.A. McGregor, and M.S. Choi Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism Mol Nutr Food Res 55 2011 1829 1840
324. R.A. Disilvestro, E. Joseph, S. Zhao, and J. Bosmer Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people Nutr J 11 2012 79
325. A. Mohammadi, A. Sahebkar, M. Iranshahi, M. Amini, R. Khojasteh, and M. Ghayour-Mobarhan et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial Phytother Res 27 2013 374 379
326. Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med. http://dx.doi.org/10.1016/j.ctim.2014.07. 006.
327. L.X. Na, Y. Li, H.Z. Pan, X.L. Zhou, D.J. Sun, and M. Meng et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial Mol Nutr Food Res 57 2013 1569 1577
328. P.G. Bradford Curcumin and obesity Biofactors 39 2013 78 87
329. S. Chuengsamarn, S. Rattanamongkolgul, R. Luechapudiporn, C. Phisalaphong, and S. Jirawatnotai Curcumin extract for prevention of type 2 diabetes Diabetes Care 35 2012 2121 2127
330. G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P.S.S.R. Srinivas Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers Planta Med 64 1998 353 356
331. J. Cuomo, G. Appendino, A.S. Dern, E. Schneider, T.P. McKinnon, and M.J. Brown et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation J Nat Prod 74 2011 664 669
332. S.C. Gupta, S. Patchva, and B.B. Aggarwal Therapeutic roles of curcumin: lessons learned from clinical trials AAPS J 15 2013 195 218
333. Available at < http://www.catabasis.com/scitech.php >; 2014 [last accessed 28.06.14].
334. Donovan JM, Dunbar R, Biernat L, et al. Phase I single and multiple ascending dose study of CAT-2003, a novel activator of lipoprotein lipase, demonstrates reductions in postprandial triglycerides. Poster presented at: National Lipid Association Scientific Sessions; May 1-4, 2014; Orlando FL. Poster #119.
335. Donovan J, Dunbar R, Biernat L, Logan D, Curtis M, Mancini M, et al. Phase 1 single and multiple ascending dose study of CAT-2003, a Novel activator of lipoprotein lipase, demonstrates reductions in postprandial triglycerides [Poster Presentation] JACC March 2014 Notes: 63rd Annual Scientific Session of the American College of Cardiology, Washington, DC, March 2014.
336. D.P. Bartel MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2004 281 297
337. E. Flowers, E.S. Froelicher, and B.E. Aouizerat MicroRNA regulation of lipid metabolism Metabolism 62 2013 12 20
338. C. Fernández-Hernando, Y. Suárez, K.J. Rayner, and K.J. Moore MicroRNAs in lipid metabolism Curr Opin Lipidol 22 2011 86 92
339. D. Iliopoulos, K. Drosatos, Y. Hiyama, I.J. Goldberg, and V.I. Zannis MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism J Lipid Res 51 2010 1513 1523
340. C. Esau, S. Davis, S.F. Murray, X.X. Yu, S.K. Pandey, and M. Pear et al. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting Cell Metab 3 2006 87 98
341. J. Krützfeldt, N. Rajewsky, R. Braich, K.G. Rajeev, T. Tuschl, and M. Ma-noharan et al. Silencing of microRNAs in vivo with 'antagomirs' Nature 438 2005 685 689
342. W.C. Tsai, S.D. Hsu, C.S. Hsu, T.C. Lai, S.J. Chen, and R. Shen et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis J Clin Invest 122 2012 2884 2897
343. S.H. Hsu, B. Wang, J. Kota, J. Yu, S. Costinean, and H. Kutay et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver J Clin Invest 122 2012 2871 2883
344. K.J. Rayner, C.C. Esau, F.N. Hussain, A.L. McDaniel, S.M. Marshall, and J.M. van Gils et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides Nature 478 2011 404 407
345. A. Dávalos, L. Goedeke, P. Smibert, C.M. Ramírez, N.P. Warrier, and U. Andreo et al. MiR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling Proc Natl Acad Sci U S A 108 2011 9232 9237
346. C.T. Johansen, and R.A. Hegele Using Mendelian randomization to determine causative factors in cardiovascular disease J Intern Med 273 2013 44 47
347. A.B. Jørgensen, R. Frikke-Schmidt, A.S. West, P. Grande, B.G. Nordestgaard, and A. Tybjærg-Hansen Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction Eur Heart J 34 2013 1826 1833
348. M. Laakso, S. Lehto, I. Penttilä, and K. Pyörälä Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes Circulation 88 1993 1421 1430
349. W. Lu, H.E. Resnick, K.A. Jablonski, K.L. Jones, A.K. Jain, and W.J. Howard et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study Diabetes Care 26 2003 16 23
350. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
351. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
352. S.M. Grundy, J.I. Cleeman, C.N. Bairey Merz, J.B. Brewer Jr., L.T. Clark, and D.B. Hunninghake et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
353. S.M. Grundy, H. Arai, P. Barter, T.P. Bersot, D.J. Betteridge, and R. Carmena et al. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia - full report J Clin Lipidol 8 2014 29 60
354. J. Donovan, R. Dunbar, L. Biernat, D. Logan, M. Curtis, and M. Mancini et al. Phase 1 single and multiple ascending dose study of CAT-2003, a novel activator of lipoprotein lipase, demonstrates reductions in postprandial triglycerides J Am Coll Cardiol 63 2014 A1450
355. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; pii:S0735-1097(13)06028-2.
356. JBS3 Board Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart 100 2014 ii1 ii67